SCHEMBL1501928

SCHEMBL1501928

CC(=O)NCC1CN(CC2CCN(C(=O)OC(C)(C)C)CC2)CCO1

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.44
▸ PKM P14618 1/20 0.44
▸ RECQL P46063 1/20 0.40
▸ USP2 O75604 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ GPR119 Q8TDV5 1/20 0.38
▸ EPHX1 P07099 1/20 0.38
▸ TGFBR1 P36897 2/20 0.37
▸ HPGD P15428 1/20 0.37
▸ FAAH O00519 1/20 0.37
▸ GNRHR P30968 1/20 0.37
▸ FPR2 P25090 1/20 0.36
▸ NAMPT P43490 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ IDO1 P14902 1/20 0.36
▸ TDO2 P48775 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1501976 0.85 DRD2 (0.43) KDM4EPKMEPHX1
SCHEMBL3405857 0.84 RECQL (0.43) KDM4EPKMRECQLUSP2SMN1; SMN2
SCHEMBL1501922 0.84 RECQL (0.43) KDM4EPKMRECQLUSP2SMN1; SMN2
SCHEMBL3402630 0.84 RECQL (0.43) KDM4EPKMRECQLUSP2SMN1; SMN2
SCHEMBL16035768 0.83 USP2 (0.47) KDM4EPKMRECQLUSP2SMN1; SMN2
SCHEMBL16035767 0.83 USP2 (0.47) KDM4EPKMRECQLUSP2SMN1; SMN2
SCHEMBL1501980 0.82 KDM4E (0.49) KDM4EPKMSMN1; SMN2GPR119MAPT
SCHEMBL1501984 0.82 KDM4E (0.49) KDM4EPKMSMN1; SMN2GPR119MAPT
SCHEMBL1245476 0.79 KDM4E (0.64) KDM4EPKMRECQLUSP2SMN1; SMN2
SCHEMBL12759030 0.78 MEN1 (0.44) KDM4EPKMRECQLUSP2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102015697-B Amide derivatives and pharmaceutical compositions containing the same DAINIPPON SUMITOMO PHARMA CO 2015-06-17 — — CN disclosed
EP-2256114-B1 AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME DAINIPPON SUMITOMO PHARMA CO (JP) 2014-06-25 — — EP disclosed
US-7906510-B2 Amide derivative and pharmaceutical composition containing the same Dainippon Sumito Pharma Co., Ltd. (JP) 2011-03-15 — — US disclosed
US-7906510-B2 Amide derivative and pharmaceutical composition containing the same Dainippon Sumito Pharma Co., Ltd. (JP) 2011-03-15 — — US disclosed
EP-2256114-A1 AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME Dainippon Sumitomo Pharma Co., Ltd. (JP) 2010-12-01 — — EP disclosed
US-20100249399-A1 AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME Sumitomo Pharma Co., Ltd. (JP) 2010-09-30 — — US disclosed
US-20100249399-A1 AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME Sumitomo Pharma Co., Ltd. (JP) 2010-09-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249399-A1 AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME HTR4, MC2R, HTR1D KDM4E 4027/4885PKM 3185/4885RECQL 3351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback